StockData

MOGU vs OptimizeRx

MOGU and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MOGU and OPRX compare

OptimizeRx grew revenue faster over the last twelve months (−5.8% versus −11.2% for MOGU).

OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with 1.5% at MOGU.

OptimizeRx scores higher on the StockData Score (10 against 5 for MOGU), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMOGUOPRX
Size and price
Market cap–$131M
Share price$1.88$6.94
Change, 1 year−30.1%−54.3%
Change, 5 years−79.1%−89.9%
Beta (5Y)1.321.50
Employees274104
StockData Score
Total score510 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score12 (better)
Health score4 (better)3
Dividend score00
Valuation
P/E–28.9×
P/S–1.3×
P/B–1.0×
EV/EBITDA–8.3×
P/FCF–7.1×
FCF yield–14.0%
Fair value–$9.96
Margin of safety–30.4%
Growth
Revenue growth (TTM)−11.2%−5.8% (better)
Revenue growth, 5Y average−23.6%20.4% (better)
Profitability
Gross margin28.6%73.2% (better)
Operating margin−57.6%11.1% (better)
Net margin1.5%4.7% (better)
FCF margin−41.1%18.6% (better)
Return on equity0.36%3.7% (better)
Return on invested capital−21.1%5.8% (better)
Financial health
Debt / equity0.000.15 (better)
Net debt / EBITDA–−0.33
Interest coverage−6564.7×2.3× (better)
Current ratio1.075.58 (better)
Altman Z-score–2.82
Piotroski F-score38 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.06%59.6%
Held by insiders12.8%19.4%
Insider net buying, 12 months$54.9K (better)−$18.8K
Superinvestors holding1–
Short interest, % of float–7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.